News | August 16, 2022
ResMed Q4 revenue up 4%; operating profit up 6%
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Company appoints five new independent directors to reconstituted board
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Subscribe To Our Newsletter & Stay Updated
